<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816698</url>
  </required_header>
  <id_info>
    <org_study_id>GZS01167262</org_study_id>
    <nct_id>NCT01816698</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Taurine Granule on Blood Pressure in Prehypertensive</brief_title>
  <acronym>ESTAB</acronym>
  <official_title>A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of TAURINE GRANULE and Placebo on Blood Pressure in Prehypertensive.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiming Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prehypertension are associated with an increased risk of atherosclerosis and coronary artery&#xD;
      disease, and often complicated with the metabolic disorder of glucose and lipid. The&#xD;
      comprehensive prevention of hypertension is still an important and complex clinical issue.&#xD;
      Taurine is one of the ingredients of Chinese medicine bezoar ,as an endogenous amino acids is&#xD;
      central inhibitory neurotransmitter, can regulate the excitability of nerve tissue, regulate&#xD;
      body temperature, therefore, antipyretic, sedative, analgesic, anti-inflammatory,the role of&#xD;
      anti-rheumatic, anti-convulsant. In addition, Taurine inhibits platelet aggregation in the&#xD;
      circulatory system, lower blood lipids, to maintain the body's normal blood pressure and&#xD;
      prevent atherosclerosis; protective effect on myocardial cells, can be anti-arrhythmic;&#xD;
      special efficacy to lower blood cholesterol, to treat heart failure. The effect of oral&#xD;
      Taurine on blood pressure is not consistent, however, many animal study has shown that oral&#xD;
      administration of Taurine, could reduce 24-hour mean arterial systolic and diastolic blood&#xD;
      pressure in spontaneous hypertensive rats. Furthermore, Taurine interfere with calcium and&#xD;
      low affinity binding of the calcium binding sites, decrease the voltage-dependent Ca2+channel&#xD;
      in vascular smooth muscle relaxation, vasodilation, lower blood pressure.In a prospective,&#xD;
      double-blind, randomized, and parallel-group study, we will evaluate the effects of Taurine&#xD;
      granule on blood pressure and metabolic parameters in prehypertensive and mild hypertensive&#xD;
      patients. This study will help develop future comprehensive prevention and treatment&#xD;
      strategies for hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease in blood pressure after an 12-week oral Taurine granule administration.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the effects of Taurine granule on blood pressure and metabolic parameters in prehypertensive patients after an 12-week oral administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Prehypertension</condition>
  <arm_group>
    <arm_group_label>Taurine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions Drug: Taurine granule Arms: Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interventions Drug: Placebo Arms: Group 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurine granule</intervention_name>
    <description>1 package(1.6g taurine granule) once a day after meals, 12 weeks</description>
    <arm_group_label>Taurine</arm_group_label>
    <other_name>Taurine granule, H20003861.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 1 package once a day after meals, 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo packaged similar to Taurine granule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood pressure: 120mmHg≤SBP&lt;140mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Hypertension: SBP≥140mmHg, or DBP≥90mmHg.&#xD;
&#xD;
          -  known allergy to trial drugs&#xD;
&#xD;
          -  Myocardial infarction or cerebrovascular accident in the year preceding the trial&#xD;
&#xD;
          -  Clinical Congestive Heart Failure&#xD;
&#xD;
          -  Secondary hypertension&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Malignant tumor&#xD;
&#xD;
          -  Gastroesophageal reflux or gastroduodenal ulcer&#xD;
&#xD;
          -  History of hepatitis or cirrhosis&#xD;
&#xD;
          -  History of kidney disease&#xD;
&#xD;
          -  Body weight﹤35Kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The third hospital affiliated to the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhiming Zhu</investigator_full_name>
    <investigator_title>Chief Scientist of the National Key Basic Research and Development Program (973 Program)</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Taurine</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

